HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Online CME Information Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rubin, B. K. Articles by Henke, M. O. Search for Related Content PubMed PubMed Citation Articles by Rubin, B. K. Articles by Henke, M. O.

Immunomodulatory Activity and Effectiveness of Macrolides in Chronic Airway Disease^*

^* From the Department of Pediatrics (Dr. Rubin), Wake Forest University School of Medicine, Winston-Salem, NC; and Department of Pulmonary Medicine (Dr. Henke), Philipps-University Marburg, Marburg, Germany.

Correspondence to: Bruce K. Rubin, MD, MEngr, FCCP, Professor and Vice-Chair, Department of Pediatrics, Professor of Biomedical Engineering, Physiology, and Pharmacology, Wake Forest University School of Medicine, Winston-Salem, NC 27157-1081; e-mail: brubin{at}wfubmc.edu

The use of troleandomycin as adjunctive therapy for the treatment of patients with corticosteroid-dependent asthma first suggested an immunomodulatory effect of the macrolide antibiotics. This led to studies of the macrolides in other chronic airway diseases, such as diffuse panbronchiolitis (DPB), a disease occurring primarily in East Asia. The use of macrolides for the therapy of patients with DPB has led to dramatic improvements in pulmonary function and prolonged survival. Similar benefits have been documented in Japanese studies of bronchiectasis, chronic bronchitis, and sinobronchial syndrome. Clinical and pathologic similarities between DPB and cystic fibrosis (CF) led to the investigation of macrolides for the treatment of CF. Data now suggest that persons with CF will benefit from macrolide therapy. In vitro and in vivo studies suggest that macrolides may inhibit the pulmonary influx of neutrophils, inhibit the release of proinflammatory cytokines, protect the epithelium from bioactive phospholipids, and improve the transportability of airway secretions. The immunomodulatory effects of the macrolides also may be beneficial for the treatment of other chronic inflammatory conditions.

Key Words: azithromycin • clarithromycin • cystic fibrosis • cytokines • diffuse panbronchiolitis • erythromycin • macrolide antibiotics • neutrophil • troleandomycin

This article has been cited by other articles:

				A. Knyazhitskiy, R. G. Masson, R. Corkey, and J. Joiner Beneficial Response to Macrolide Antibiotic in a Patient With Desquamative Interstitial Pneumonia Refractory to Corticosteroid Therapy Chest, July 1, 2008; 134(1): 185 - 187. [Abstract] [Full Text] [PDF]

				R. W. Vandivier, P. M. Henson, and I. S. Douglas Burying the Dead: The Impact of Failed Apoptotic Cell Removal (Efferocytosis) on Chronic Inflammatory Lung Disease Chest, June 1, 2006; 129(6): 1673 - 1682. [Abstract] [Full Text] [PDF]

				M. Yasutomi, Y. Ohshima, N. Omata, A. Yamada, H. Iwasaki, Y. Urasaki, and M. Mayumi Erythromycin Differentially Inhibits Lipopolysaccharide- or Poly(I:C)-Induced but Not Peptidoglycan-Induced Activation of Human Monocyte-Derived Dendritic Cells J. Immunol., December 15, 2005; 175(12): 8069 - 8076. [Abstract] [Full Text] [PDF]

				S. L. Johnston and R. J. Martin Chlamydophila pneumoniae and Mycoplasma pneumoniae: A Role in Asthma Pathogenesis? Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1078 - 1089. [Abstract] [Full Text] [PDF]

				A. M. Rios, M. Fonseca-Aten, A. Mejias, S. Chavez-Bueno, K. Katz, A. M. Gomez, G. H. McCracken Jr., O. Ramilo, and R. D. Hardy Microbiologic and Immunologic Evaluation of a Single High Dose of Azithromycin for Treatment of Experimental Mycoplasma pneumoniae Pneumonia Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3970 - 3973. [Abstract] [Full Text] [PDF]

				T. Wagner, G. Soong, S. Sokol, L. Saiman, and A. Prince Effects of Azithromycin on Clinical Isolates of Pseudomonas aeruginosa From Cystic Fibrosis Patients Chest, August 1, 2005; 128(2): 912 - 919. [Abstract] [Full Text] [PDF]

				P. J. Barnes and R. A. Stockley COPD: current therapeutic interventions and future approaches Eur. Respir. J., June 1, 2005; 25(6): 1084 - 1106. [Abstract] [Full Text] [PDF]

				T. Pallasch, D. L. Brown, L. M. Golub, and J. G. Thomas Subantimicrobial Doses of Tetracycline Arterioscler. Thromb. Vasc. Biol., September 1, 2004; 24(9): e163 - e163. [Full Text] [PDF]